



## **Important News from the San Antonio Metropolitan Health District (SAMHD) October 21, 2011**

---

### **Revised Guidelines for the Usage for Meningococcal Conjugate Vaccines (MCV4)**

This will provide information from the October 14, 2011, Morbidity and Mortality Weekly Report (MMWR) for the *Recommendation of the Advisory Committee on Immunization Practices (ACIP) for Use of Quadrivalent Meningococcal Conjugate Vaccine (MenACWY-D) Among Children Aged 9 Through 23 Months at Increased Risk for Invasive Meningococcal Disease*. In June, the ACIP approved these updated recommendations for the use of quadrivalent (serogroups A, C, Y, and W-135) meningococcal conjugate vaccine, Menactra (Sanofi Pasteur), for the specified risk groups. In addition, the FDA approved the use of Menactra in children as young as 9 months in April, 2011. The ACIP high-risk recommendation is to recognize that all infants < 1 year have higher rates of disease compared to other age groups. In addition, others considered at increased risk are infants with complement component deficiencies, infants in a defined risk group for a community or institutional outbreak, infants traveling to an area where meningococcal disease is epidemic or highly endemic [infants with functional or anatomic asplenia were not considered for this group]. Children aged 9 through 23 months at increased risk for meningococcal disease should receive a 2-dose series of Menactra, 3 months apart. Those requiring protection prior to travel can receive the second dose as early as 2 months after the first dose.

This information supplements the February 2011 memo from Metro Health VFC program discussing the previous ACIP recommendations for a booster dose of the meningococcal vaccines.

The ACIP VFC Resolution is available at:

[www.cdc.gov/vaccines/programs/vfc/downloads/resolutions/06-11mening-mcv.pdf](http://www.cdc.gov/vaccines/programs/vfc/downloads/resolutions/06-11mening-mcv.pdf)

Specific information about this recommendation is available at:

[http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6040a4.htm?s\\_cid=mm6040a4\\_e%0d%0a](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6040a4.htm?s_cid=mm6040a4_e%0d%0a)

If you have questions about this information please call Kenya Wilson at 207-3974, or Anthony Johnson at 207-4015.

The following chart outlines the revised guidelines for use of the MCV4 vaccine for your VFC-eligible patients (Note: the dose interval information in the 'booster dose' column has been revised by ACIP from what appeared in the February 2011 Memo):

## ACIP Summary of Meningococcal Conjugate Vaccine (MCV4) Recommendations

Age	Subgroup	Primary Vaccination	Booster Dose
9 through 23 months of age, with high risk conditions	Children with complement deficiencies;	Two doses of MCV4 (Menactra), three months apart`	<b>If first dose received at age 9 months through 6 years and remain at increased risk for meningococcal disease</b> , should receive an additional dose of MCV4, 3 years after primary vaccination. Boosters should be repeated every 5 years thereafter.
	Children with HIV, if another indication for vaccination exists	Two doses of MCV4, three months apart	
	All others in this age group recommended for vaccination (travelers to the Meningitis Belt, etc)	Two doses of MCV4 , three months apart (infants receiving the vaccine prior to travel can receive the doses as early as two months apart)	
2 through 18 years of age, with high risk conditions *	Children with complement deficiencies; functional or anatomic asplenia;	Two doses of MCV4 (Menactra or Menveo), two months apart	<b>If first dose received at age 7 years or older and remain at increased risk for meningococcal disease</b> , should receive an additional dose of MCV4, 5 years after primary vaccination. Boosters should be repeated every 5 years thereafter.
	Children with HIV, if another indication for vaccination exists	Two doses of MCV4 (Menactra or Menveo), two months apart	
	All others in this age group recommended for vaccination (travelers to the Meningitis Belt, etc)	Single dose of MCV4 (Menactra or Menveo)	
All other children 11-18 years of age	Routine vaccination with MCV4 (Menactra or Menveo) at ages 11 through 12 years		<b>If vaccinated at age 11 through 12 years</b> , should receive a one-time booster dose at age 16 years  <b>If vaccinated at age 13 through 15 years</b> , should receive a one-time booster dose at age 16 through 18 years

\* Includes children who have complement deficiencies (e.g., C5-C9, properidin, factor H, or factor), anatomic or functional asplenia, and children with HIV infection; travelers to or residents of countries in which meningococcal disease is hyperendemic or epidemic; and children who are who are part of a community outbreak of a vaccine-preventable serogroup

At the time of this resolution, there are currently two licensed MCV4 products - Menactra is manufactured by sanofi pasteur and is licensed for use in persons aged 9 months through 55 years of age, and Menveo which is manufactured by Novartis Vaccines and Diagnostics, Inc. and is licensed for use in persons aged 2 through 55 years of age. Prescribing information (PI) for these products is located at:

Menveo - <http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM201349.pdf>

Menactra - <http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM131170.pdf>